A new GLP-1 weight loss drug called survodutide has shown promising results in a phase 3 clinical trial. The drug, which ...

Learn more Eli Lilly raised its full-year 2026 revenue guidance to between $82 billion and $85 billion after first-quarter ...

Discover how to get Zepbound, including the eligibility requirements, cost, insurance coverage and where to find it. Zepbound ...

Eli Lilly shares jumped after the drugmaker posted earnings that topped estimates and hiked its outlook, thanks to booming ...

Eli Lilly leads GLP-1s but faces rising Novo competition; DCF fair value is $956 vs. $960. Click here to read this latest ...

Discover how Eli Lilly is increasing medical weight loss access in Indiana through Zepbound vials. Learn how this Indy ...

Lilly heads into Q1 earnings with GLP-1 drugs driving growth. However, pricing pressure, rising costs, and softer Foundayo ...

About 1 in 8 Americans have used GLP-1s for weight loss — but more than three-quarters quit taking them within two years.

Obesity drug giant Eli Lilly on Thursday reported a monster first quarter, fortifying our conviction to stick with the stock ...

Eli Lilly (LLY) stock dropped 3% on Foundayo liver concerns. Analysts say the decline is overdone and recommend buying the ...

"Regulatory reviews are ongoing in over 40 countries" and "we plan to submit Foundayo in the U.S. for type 2 diabetes later this quarter" (Chairman & CEO Ricks). "Revenue grew 56% compared to Q1 2025" ...

And it's not too late to get in on the action.